Athersys (FRA:4LSA) ROCE % : 0.00% (As of Sep. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Athersys ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Athersys's annualized ROCE % for the quarter that ended in Sep. 2023 was 0.00%.

Athersys ROCE % Historical Data

The historical data trend for Athersys's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys ROCE % Chart

Athersys Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-74.54

-122.93

-229.29

-270.09

-869.41

Athersys Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Athersys ROCE % Calculation

Athersys's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-72.696	/	( ( (53.263 - 26.427)	+	(26.178 - 36.291) )	/ 2 )
	=	-72.696	/	( (26.836	+	-10.113)	/ 2 )
	=	-72.696	/	8.3615
	=	-869.41 %

Athersys's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-29.16	/	( ( (9.67 - 39.409)	+	(6.96 - 36.191) )	/ 2 )
	=	-29.16	/	( ( -29.739	+	-29.231 )	/ 2 )
	=	-29.16	/	-29.485
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Athersys (FRA:4LSA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Athersys ROCE % Related Terms

Thank you for viewing the detailed overview of Athersys's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Athersys (FRA:4LSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (FRA:4LSA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ATHXQ:USA

Address

3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634

Website

https://www.athersys.com

Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Athersys (FRA:4LSA) Headlines

No Headlines